样式: 排序: IF: - GO 导出 标记为已读
-
To flare or not to flare: patients’ and rheumatologists’ perceptions on the on-flare retreatment strategy of rituximab in rheumatoid arthritis Thera. Adv. Musculoskelet. Dis. (IF 4.2) Pub Date : 2024-02-28 Delphine Bertrand, Anke Deprez, Michaël Doumen, Diederik De Cock, Sofia Pazmino, Anja Marchal, Marc Thelissen, Johan Joly, Elias De Meyst, Barbara Neerinckx, René Westhovens, Patrick Verschueren
Background:Several retreatment strategies exist for rituximab in rheumatoid arthritis (RA). In some countries, reimbursement criteria require a loss of disease control for rituximab retreatment. Understanding the patients’ and rheumatologists’ perceptions regarding this retreatment strategy would be informative in identifying the optimal treatment administration schedule.Objectives:This study aimed
-
Impact of daily physical therapy over 2 weeks on spinal mobility including objective electronic measurements and function in patients with axial spondyloarthritis Thera. Adv. Musculoskelet. Dis. (IF 4.2) Pub Date : 2024-02-23 David Kiefer, Lucia Schneider, Juergen Braun, Uta Kiltz, Niklas Kolle, Ioana Andreica, Styliani Tsiami, Bjoern Buehring, Philipp Sewerin, Susanne Herbold, Xenofon Baraliakos
Background:Patients with axial spondyloarthritis (axSpA) are often compromised by impaired function and mobility. The standardized 2-week inpatient program ‘multimodal rheumatologic complex treatment’ (MRCT) was designed for patients with axSpA. The Epionics SPINE (ES) is an objective tool validated to assess mobility.Objective:To investigate the impact of MRCT on physical function and mobility including
-
Effects of adipose-derived mesenchymal stem cell conditioned medium on human tenocytes exposed to high glucose Thera. Adv. Musculoskelet. Dis. (IF 4.2) Pub Date : 2024-01-08 Maria Consiglia Trotta, Annalisa Itro, Caterina Claudia Lepre, Marina Russo, Francesca Guida, Antimo Moretti, Adriano Braile, Umberto Tarantino, Michele D’Amico, Giuseppe Toro
Introduction:Diabetic tendinopathy is a common invalidating and challenging disease that may be treated using stem cells. However, the effects of adipose-derived mesenchymal stem cell conditioned medium (ASC-CM) in diabetic tendinopathy have never been explored.Objectives:The present study evaluated the effects of ASC-CM on morphology, cell viability, structure, and scratch wound closure of human tenocytes
-
The role of the fracture liaison service in the prevention of atypical femoral fractures. Thera. Adv. Musculoskelet. Dis. (IF 4.2) Pub Date : 2023-11-28 Giuseppe Toro,Adriano Braile,Sara Liguori,Antimo Moretti,Giovanni Landi,Antonio Benedetto Cecere,Gianluca Conza,Annalisa De Cicco,Umberto Tarantino,Giovanni Iolascon
Osteoporosis and fragility fractures (FFs) are considered critical health problems by the World Health Organization (WHO) because of high morbidity, mortality, and healthcare costs. The occurrence of a FF raises the risk of a subsequent fracture (refracture). The hip is the most common site of fragility refracture, and its onset is associated with a further increase in patient's morbidity, mortality
-
Effects of TNF-α inhibition versus secukinumab on active ultrasound-confirmed enthesitis in psoriatic arthritis. Thera. Adv. Musculoskelet. Dis. (IF 4.2) Pub Date : 2023-11-16 Ashley Elliott,Gary Wright,Adrian Pendleton,Madeleine Rooney
Introduction Enthesitis is a hallmark of psoriatic disease, but its clinical assessment is problematic in terms of diagnostic sensitivity and overlap with other comorbid conditions. Ultrasound is a useful tool that can give a more detailed assessment of enthesitis. Research demonstrates that those with persistent ultrasound entheseal disease are at risk of progressive articular damage. With limited
-
Rheumatoid arthritis disease activity and adverse events in patients receiving tofacitinib or tumor necrosis factor inhibitors: a post hoc analysis of ORAL Surveillance. Thera. Adv. Musculoskelet. Dis. (IF 4.2) Pub Date : 2023-11-06 George A Karpouzas,Zoltán Szekanecz,Eva Baecklund,Ted R Mikuls,Deepak L Bhatt,Cunshan Wang,Gosford A Sawyerr,Yan Chen,Sujatha Menon,Carol A Connell,Steven R Ytterberg,Mahta Mortezavi
Background In patients with rheumatoid arthritis (RA), persistent inflammation and increasing disease activity are associated with increased risk of adverse events (AEs). Objectives To assess relationships between RA disease activity and AEs of interest in patients treated with tofacitinib or tumor necrosis factor inhibitors (TNFi). Design This was a post hoc analysis of a long-term, postauthorization
-
The predictability of ASDAS on drug survival in patients with ankylosing spondylitis on biologic therapy: data from the KOBIO registry. Thera. Adv. Musculoskelet. Dis. (IF 4.2) Pub Date : 2023-10-09 Jinhyun Kim,Min Jung Kim,Geun Young Oh,Sun Kyung Lee,Taeeun Kim,Kichul Shin
Background The Ankylosing Spondylitis (AS) Disease Activity Score (ASDAS) is largely used for assessing disease activity in patients with AS. Objectives We aimed to investigate the predictability of ASDAS on drug survival in patients with low Bath AS Disease Activity Index (BASDAI) during biologic therapy. Design Using data from multi-center, prospective, observational prospective cohort, Korean College
-
Impact of csDMARDs adherence on clinical remission in patients with new-onset inflammatory arthritis: a prospective cohort study from the ELECTRA database. Thera. Adv. Musculoskelet. Dis. (IF 4.2) Pub Date : 2023-10-04 Anna Zanetti,Antonella Zambon,Carlo A Scirè,Serena Bugatti,Carlomaurizio Montecucco,Garifallia Sakellariou
Background Major improvements in the management of rheumatoid arthritis (RA) have made clinical remission an achievable and desirable goal but, despite the relevance gained by a profound disease suppression, many patients with RA still miss clinical remission due to several factors influencing disease activity, including treatment adherence. Objective To evaluate the effect of adherence to conventional
-
Factors associated with radiographic progression in rheumatoid arthritis starting biological diseases modifying anti-rheumatic drugs (bDMARDs). Thera. Adv. Musculoskelet. Dis. (IF 4.2) Pub Date : 2023-09-28 Giovanni Adami,Angelo Fassio,Francesca Pistillo,Camilla Benini,Ombretta Viapiana,Maurizio Rossini,Davide Gatti
Background Biological DMARDs (bDMARDs) have been proven to prevent joint damage and bone erosions. Nevertheless, approximately 15% of rheumatoid arthritis (RA) patients on bDMARDs will progress despite good control of joint inflammation. Objectives The objective of our study is to investigate the factors associated with radiological progression of patients treated with bDMARDs. Design We conducted
-
The burden of low back pain in children and adolescents with overweight and obesity: from pathophysiology to prevention and treatment strategies. Thera. Adv. Musculoskelet. Dis. (IF 4.2) Pub Date : 2023-09-08 Luca Ambrosio,Giorgia Mazzuca,Alice Maguolo,Fabrizio Russo,Francesca Cannata,Gianluca Vadalà,Claudio Maffeis,Rocco Papalia,Vincenzo Denaro
Nonspecific low back pain (LBP) is one of the most common causes of disability, affecting all individuals at least once in their lifetime. Such a condition is also becoming increasingly frequent in the pediatric population, especially in children and adolescents with overweight/obesity. Furthermore, new-onset LBP during adolescence has been demonstrated to be a strong predictor of developing LBP later
-
Treatment with adalimumab in patients with chronic inflammatory rheumatic diseases: a study of treatment trajectories on a patient level in routine care. Thera. Adv. Musculoskelet. Dis. (IF 4.2) Pub Date : 2023-09-08 Imke Redeker,Stefan Moustakis,Styliani Tsiami,Xenofon Baraliakos,Ioana Andreica,Bjoern Buehring,Jürgen Braun,Uta Kiltz
Background Previous experiences with non-medical switching of adalimumab (ADA) in patients with chronic inflammatory rheumatic diseases (CIRD) come mainly from phase III extension of randomised clinical trials and little from routine care. Objectives To analyse treatment trajectories over 2 years in patients with CIRD conducting a non-medical switch from originator to biosimilar ADA. Design A retrospective
-
Application of clinical and molecular profiling data to improve patient outcomes in psoriatic arthritis. Thera. Adv. Musculoskelet. Dis. (IF 4.2) Pub Date : 2023-09-08 Oliver FitzGerald,Frank Behrens,Anne Barton,Heidi Bertheussen,Bruno Boutouyrie-Dumont,Laura Coates,Owen Davies,Maarten de Wit,Filippo Fagni,Carl S Goodyear,Robert Gurke,Lisa Hahnefeld,Christine Huppertz,Vassilios Ioannidis,Mark Ibberson,Arnon Katz,Maximilian Klippstein,Michaela Koehm,Shimon Korish,Sina Mackay,David A Martin,Denis O'Sullivan,Khadijah Patel,Stefan Rueping,Georg Schett,Klaus Scholich
Achieving a good outcome for a person with Psoriatic Arthritis (PsA) is made difficult by late diagnosis, heterogenous clinical disease expression and in many cases, failure to adequately suppress inflammatory disease features. Single-centre studies have certainly contributed to our understanding of disease pathogenesis, but to adequately address the major areas of unmet need, multi-partner, collaborative
-
Anti-sclerostin antibodies: a new frontier in fragility fractures treatment. Thera. Adv. Musculoskelet. Dis. (IF 4.2) Pub Date : 2023-09-08 Giovanni Iolascon,Sara Liguori,Marco Paoletta,Giuseppe Toro,Antimo Moretti
Bone fragility is the determinant of the increased risk of minimal trauma fracture and must be treated with a multimodal approach that includes pharmacological therapy, physical exercise, and adequate nutrition. Pharmacological therapy, to date based on the administration of antiresorptive drugs, such as bisphosphonates and denosumab, or osteoanabolic drugs, such as teriparatide and abaloparatide,
-
Achievement of higher thresholds of clinical responses and lower levels of disease activity is associated with improvements in workplace and household productivity in patients with axial spondyloarthritis. Thera. Adv. Musculoskelet. Dis. (IF 4.2) Pub Date : 2023-08-30 Martin Rudwaleit,Pedro M Machado,Vanessa Taieb,Natasha de Peyrecave,Bengt Hoepken,Lianne S Gensler
Background Patients with active axial spondyloarthritis (axSpA) exhibit more absences and lower levels of productivity in the workplace and household than the general population, which can improve upon treatment. Objectives The objective of this study is to determine the long-term impact of achieving different levels of clinical response or disease activity on workplace and household productivity in
-
Dysfunctional high-density lipoprotein in chronic inflammatory rheumatic diseases. Thera. Adv. Musculoskelet. Dis. (IF 4.2) Pub Date : 2023-08-25 Sabina Waldecker-Gall,Felix Seibert,Sebastian Bertram,Adrian Doevelaar,Jürgen Braun,Xenofon Baraliakos,Nina Babel,Christoph Waldecker,Linda Scharow,Nikolaos Pagonas,Timm H Westhoff
Background The mechanism explaining low cholesterol concentrations in chronic inflammatory rheumatic disease (CIRD) is incompletely understood. We hypothesized that chronic inflammation impairs the functionality of high-density lipoprotein (HDL), for example, by oxidative processes. Objectives Assessment of oxidized HDL (HDLox), a marker of dysfunctional HDL, in newly diagnosed patients with CIRD before
-
The effect of ixekizumab on axial manifestations in patients with psoriatic arthritis from two phase III clinical trials: SPIRIT-P1 and SPIRIT-P2. Thera. Adv. Musculoskelet. Dis. (IF 4.2) Pub Date : 2023-08-24 Atul Deodhar,Dafna Gladman,Rebecca Bolce,David Sandoval,So Young Park,Soyi Liu Leage,Peter Nash,Denis Poddubnyy
Background Psoriatic arthritis (PsA) is a chronic inflammatory condition predominantly affecting the peripheral joints. However, some patients with PsA can experience axial involvement which is manifested with back pain and associated with increased burden of illness. Objectives The aim of this post hoc analysis was to determine the efficacy of ixekizumab (IXE) up to 52 weeks in reducing axial symptoms
-
Drug switching in axial spondyloarthritis patients in Germany - a social listening analysis. Thera. Adv. Musculoskelet. Dis. (IF 4.2) Pub Date : 2023-08-08 Maria Kahn,Steffeni Papukchieva,Axel Fehr,Markus Eberl,Berenice Rösler,Justyna Veit,Benjamin Friedrich,Denis Poddubnyy
Background Axial spondyloarthritis (axSpA) is a chronic inflammatory disease which primarily affects the axial skeleton resulting in chronic back pain and stiffness. According to the guideline, the first-line treatment includes non-steroidal anti-inflammatory drugs (NSAIDs), conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) and non-pharmacological treatment. Second line treatment
-
Efficacy and safety of abatacept in patients with rheumatoid arthritis with previous malignancy. Thera. Adv. Musculoskelet. Dis. (IF 4.2) Pub Date : 2023-08-01 Yosuke Kunishita,Kento Ichikawa,Yuji Uzawa,Masaki Mitsuhashi,Yuji Yoshioka,Tadanobu Okubo,Shouhei Nagaoka
Background Abatacept (ABT) is known to lower infection risk than other biologics and is effective and safe in elderly patients with rheumatoid arthritis (RA). However, there were inconsistent reports on the impact of ABT on malignancies which are more common in the elderly and strongly related to prognosis. Objectives This study aimed to evaluate the efficacy and safety of ABT in patients with RA with
-
A prognostic immune nutritional index can predict all-cause mortality in patients with antineutrophil cytoplasmic antibody-associated vasculitis. Thera. Adv. Musculoskelet. Dis. (IF 4.2) Pub Date : 2023-07-29 Sung Soo Ahn,Jung Yoon Pyo,Jason Jungsik Song,Yong-Beom Park,Sang-Won Lee
Background Studies have proposed that nutritional and immune-related markers are relevant with patient outcomes of various medical conditions and could be a useful indicator of patient prognostication. Objectives This study investigated whether a prognostic immune nutritional index (PINI) at diagnosis could predict adverse clinical outcomes in patients with antineutrophil cytoplasmic antibody-associated
-
Oral enzyme combination with bromelain, trypsin and the flavonoid rutoside reduces systemic inflammation and pain when used pre- and post-operatively in elective total hip replacement: a randomized exploratory placebo-controlled trial. Thera. Adv. Musculoskelet. Dis. (IF 4.2) Pub Date : 2023-07-29 Jiří Vosáhlo,Adam Salus,Michael Smolko,Barbora Němcová,Veit Nordmeyer,Milos Mikles,Stefanie M Rau,Odd Erik Johansen
Background Early mobilization after total hip replacement (THR) is key for fast recovery but is often limited by pain. Oral enzyme combinations (OECs) have demonstrated anti-inflammatory and pain-relieving effects. Objectives and design This prospective, randomized, double-blind, placebo-controlled exploratory trial evaluated the effects of pre- and post-operative use of OEC (90 mg bromelain, 48 mg
-
New insights in lower limb reconstruction strategies. Thera. Adv. Musculoskelet. Dis. (IF 4.2) Pub Date : 2023-07-29 Giuseppe Toro,Antonio Benedetto Cecere,Adriano Braile,Annalisa De Cicco,Sara Liguori,Umberto Tarantino,Giovanni Iolascon
High Energy Musculoskeletal Traumas (HEMTs) represent a relevant problem for healthcare systems, considering the high social costs, and both the high morbidity and mortality. The poor outcomes associated with HEMT are related to the high incidence of complications, including bone infection, fracture malunion and non-union. The treatment of each of these complications could be extremely difficult. Limb
-
Utilising a non-surgical intervention in the knee osteoarthritis care pathway: a 6-year retrospective audit on NHS patients. Thera. Adv. Musculoskelet. Dis. (IF 4.2) Pub Date : 2023-07-29 Robyn Benn,Lewis Rawson,Amanda Phillips
Background Knee osteoarthritis (OA) is a chronic, debilitating, musculoskeletal condition that affects millions. The increase in prevalence and its economic impact on healthcare and society raise the need for additional non-surgical interventions. Objective To assess the referral rates to secondary care consultation and clinical outcomes in patients with severe knee OA treated with a home-based, non-surgical
-
Myths and truths on biophysics-based approach in rehabilitation of musculoskeletal disorders. Thera. Adv. Musculoskelet. Dis. (IF 4.2) Pub Date : 2023-07-19 Alessandro de Sire,Lorenzo Lippi,Nicola Marotta,Martina Ferrillo,Arianna Folli,Alessio Turco,Antonio Ammendolia,Marco Invernizzi
Musculoskeletal disorders (MSD) are a crucial issue in current literature due to their impact on physical function, social, and economic costs. Rehabilitation plays a pivotal role in the therapeutic management of these disabling conditions with growing evidence underlining positive effects in improving functional outcomes. However, to date, several questions are still open about the mechanisms underpinning
-
Mechanisms hypothesized for pain-relieving effects of exercise in fibromyalgia: a scoping review. Thera. Adv. Musculoskelet. Dis. (IF 4.2) Pub Date : 2023-07-16 Yuva Venkata Raghava Neelapala,Domenico Mercuri,Luciana Macedo,Steven Hanna,Dylan Kobsar,Lisa Carlesso
Background Exercise is one of the most recommended management strategies by treatment guidelines for fibromyalgia (FM); however, the mechanism through which exercise improves pain in FM is still unknown. Objective We aimed to summarize the hypothesized theoretical mechanisms for the pain-relieving effects of exercise in people with FM. Eligibility Criteria Randomized controlled trials (RCTs) in English
-
Clinical characteristics of myositis patients with isolated anti-U1 ribonucleoprotein antibody resemble immune-mediated necrotizing myopathy. Thera. Adv. Musculoskelet. Dis. (IF 4.2) Pub Date : 2023-07-14 Yongpeng Ge,Hongxia Yang,Wei Jiang,Xiaolan Tian,Xin Lu,Guochun Wang
Background Anti-U1 ribonucleoprotein (U1RNP) antibodies were associated with connective tissue diseases (CTDs), but the clinical characteristics of this antibody in Chinese myositis patients have not been studied. Objective We aim to analyze the clinical features of myositis patients who test positive for anti-U1RNP antibodies and delineate a subgroup of myositis. Design This is a retrospective cohort
-
Comparative validation of the knee inflammation MRI scoring system and the MRI osteoarthritis knee score for semi-quantitative assessment of bone marrow lesions and synovitis-effusion in osteoarthritis: an international multi-reader exercise. Thera. Adv. Musculoskelet. Dis. (IF 4.2) Pub Date : 2023-07-12 Walter P Maksymowych,Jacob L Jaremko,Susanne J Pedersen,Iris Eshed,Ulrich Weber,Andrew McReynolds,Paul Bird,Stephanie Wichuk,Robert G Lambert
Background Bone marrow lesions (BMLs) and synovitis on magnetic resonance imaging (MRI) are associated with symptoms and predict degeneration of articular cartilage in osteoarthritis (OA). Validated methods for their semiquantitative assessment on MRI are available, but they all have similar scoring designs and questionable sensitivity to change. New scoring methods with completely different designs
-
Actigraphy-derived physical activity levels and circadian rhythm parameters in patients with psoriatic arthritis: relationship with disease activity, mood, age and BMI. Thera. Adv. Musculoskelet. Dis. (IF 4.2) Pub Date : 2023-07-04 Dylan McGagh,Niall McGowan,Chris Hinds,Kate E A Saunders,Laura C Coates
Background Psoriatic arthritis (PsA) is associated with sleep disturbance, depression and a lifetime risk of obesity and cardiovascular disease. To date, there have been no studies investigating the relationship between objectively-measured physical activity (PA) levels and circadian rhythm disturbance with disease activity, daily symptoms and mood in patients with PsA. Objective This pilot study aimed
-
Emerging molecular biomarkers in osteoarthritis pathology. Thera. Adv. Musculoskelet. Dis. (IF 4.2) Pub Date : 2023-06-19 Amit Sandhu,Jason S Rockel,Starlee Lively,Mohit Kapoor
Osteoarthritis (OA) is the most common form of arthritis resulting in joint discomfort and disability, culminating in decline in life quality. Attention has been drawn in recent years to disease-associated molecular biomarkers found in readily accessible biofluids due to low invasiveness of acquisition and their potential to detect early pathological molecular changes not observed with traditional
-
Medication holidays in osteoporosis: evidence-based recommendations from the Italian guidelines on 'Diagnosis, risk stratification, and continuity of care of fragility fractures' based on a systematic literature review. Thera. Adv. Musculoskelet. Dis. (IF 4.2) Pub Date : 2023-06-19 Silvia Migliaccio,Antimo Moretti,Annalisa Biffi,Raffaella Ronco,Gloria Porcu,Giovanni Adami,Rosaria Alvaro,Riccardo Bogini,Achille Patrizio Caputi,Luisella Cianferotti,Bruno Frediani,Davide Gatti,Stefano Gonnelli,Andrea Lenzi,Salvatore Leone,Tiziana Nicoletti,Marco Paoletta,Annalisa Pennini,Eleonora Piccirilli,Raffaella Michieli,Umberto Tarantino,Maurizio Rossini,Giovanni Corrao,Maria Luisa Brandi
Background Noncommunicable, chronic diseases need pharmacological interventions for long periods or even throughout life. The temporary or permanent cessation of medication for a specific period, known as a 'medication holiday,' should be planned by healthcare professionals. Objectives We evaluated the association between continuity (adherence or persistence) of treatment and several outcomes in patients
-
T-score discordance between hip and lumbar spine: risk factors and clinical implications. Thera. Adv. Musculoskelet. Dis. (IF 4.2) Pub Date : 2023-06-19 Ming-Hsiu Chiang,Yeu-Chai Jang,Yu-Pin Chen,Wing P Chan,Ying-Chin Lin,Shu-Wei Huang,Yi-Jie Kuo
Background T-score discordance is common in osteoporosis diagnosis and leads to problems for clinicians formulating treatment plans. Objectives This study investigated the potential predictors of T-score discordance and compared fracture risk among individuals with varying T-score discordance status. Design This was a single-center cross-sectional study conducted at Wan Fang Hospital, Taipei City,
-
Role of imaging for eligibility and safety of a-NGF clinical trials. Thera. Adv. Musculoskelet. Dis. (IF 4.2) Pub Date : 2023-05-29 Frank W Roemer,Marc C Hochberg,John A Carrino,Andrew J Kompel,Luis Diaz,Daichi Hayashi,Michel D Crema,Ali Guermazi
Nerve growth factor (a-NGF) inhibitors have been developed for pain treatment including symptomatic osteoarthritis (OA) and have proven analgesic efficacy and improvement in functional outcomes in patients with OA. However, despite initial promising data, a-NGF clinical trials focusing on OA treatment had been suspended in 2010. Reasons were based on concerns regarding accelerated OA progression but
-
Latest insights in disease-modifying osteoarthritis drugs development Thera. Adv. Musculoskelet. Dis. (IF 4.2) Pub Date : 2023-05-13 Shengfa Li, Peihua Cao, Tianyu Chen, Changhai Ding
Osteoarthritis (OA) is a prevalent and severely debilitating disease with an unmet medical need. In order to alleviate OA symptoms or prevent structural progression of OA, new drugs, particularly d...
-
Systemic sclerosis associated interstitial lung disease: a survey of current practices in France Thera. Adv. Musculoskelet. Dis. (IF 4.2) Pub Date : 2023-05-09 Amélie Nicolas, Sylvie Leroy, Luc Mouthon, Yurdagul Uzunhan, Vincent Cottin, Arsene Mekinian, Viviane Queyrel, Eric Hachulla, Benoit Gachet, David Launay, Nihal Martis, Groupe Orphalung, Groupe Francophone de Recherche sur la Sclérodermie
Background:Interstitial lung disease (ILD) is the leading cause of mortality in systemic sclerosis (SSc).Objective:We performed an overview of the diagnostic approaches, follow-up and treatment str...
-
Magnetic resonance imaging assessments for knee segmentation and their use in combination with machine/deep learning as predictors of early osteoarthritis diagnosis and prognosis Thera. Adv. Musculoskelet. Dis. (IF 4.2) Pub Date : 2023-04-28 Johanne Martel-Pelletier, Patrice Paiement, Jean-Pierre Pelletier
Knee osteoarthritis (OA) is a prevalent and disabling disease that can develop over decades. This disease is heterogeneous and involves structural changes in the whole joint, encompassing multiple ...
-
Association of the anti-thyroid peroxidase antibody with chronic hand pain in older adults in the Third National Health and Nutrition Examination Survey: a cross-sectional study Thera. Adv. Musculoskelet. Dis. (IF 4.2) Pub Date : 2023-04-13 Clement E. Tagoe, Wanyi Wang, Kamil E. Barbour
Background:Autoimmune thyroid disease (AITD) is the commonest autoimmune disease. Although viewed as a classic form of single-organ autoimmunity, AITD is increasingly associated with non-thyroid se...
-
Strategic application of imaging in DMOAD clinical trials: focus on eligibility, drug delivery, and semiquantitative assessment of structural progression Thera. Adv. Musculoskelet. Dis. (IF 4.2) Pub Date : 2023-04-10 Ali Guermazi, Frank W. Roemer, Michel D. Crema, Mohamed Jarraya, Ali Mobasheri, Daichi Hayashi
Despite decades of research efforts and multiple clinical trials aimed at discovering efficacious disease-modifying osteoarthritis (OA) drugs (DMOAD), we still do not have a drug that shows convinc...
-
Comparison of clinical efficiency between intra-articular injection of platelet-rich plasma and hyaluronic acid for osteoarthritis: a meta-analysis of randomized controlled trials Thera. Adv. Musculoskelet. Dis. (IF 4.2) Pub Date : 2023-03-17 Lili Chen, Shirong Jin, Yunheng Yao, Sixian He, Jinshen He
Background:Platelet-rich plasma (PRP) and hyaluronic acid (HA) are non-surgical treatments for osteoarthritis (OA), but the comparison of their efficiency is still inconclusive.Objectives:The objec...
-
An update on the use of conventional and biological disease-modifying anti-rheumatic drugs in hand osteoarthritis Thera. Adv. Musculoskelet. Dis. (IF 4.2) Pub Date : 2023-03-14 Sara Tenti, Olivier Bruyère, Sara Cheleschi, Jean-Yves Reginster, Nicola Veronese, Antonella Fioravanti
Osteoarthritis (OA) is a highly prevalent condition worldwide associated with pain, progressive disability, reduced participation in social activities, and impaired quality of life. Despite its gro...
-
Early knee OA definition–what do we know at this stage? An imaging perspective Thera. Adv. Musculoskelet. Dis. (IF 4.2) Pub Date : 2023-03-14 Xiaojuan Li, Frank W. Roemer, Flavia Cicuttini, Jamie W. MacKay, Tom Turmezei, Thomas M. Link
While criteria for early-stage knee osteoarthritis (OA) in a primary care setting have been proposed, the role of imaging has been limited to radiography using the standard Kellgren–Lawrence classi...
-
Bone fragility during the COVID-19 pandemic: the role of macro- and micronutrients Thera. Adv. Musculoskelet. Dis. (IF 4.2) Pub Date : 2023-03-14 Antimo Moretti, Sara Liguori, Marco Paoletta, Silvia Migliaccio, Giuseppe Toro, Francesca Gimigliano, Giovanni Iolascon
Bone fragility is the susceptibility to fracture due to poor bone strength. This condition is usually associated with aging, comorbidities, disability, poor quality of life, and increased mortality...
-
The application of machine learning in early diagnosis of osteoarthritis: a narrative review Thera. Adv. Musculoskelet. Dis. (IF 4.2) Pub Date : 2023-03-14 Anran Xuan, Haowei Chen, Tianyu Chen, Jia Li, Shilong Lu, Tianxiang Fan, Dong Zeng, Zhibo Wen, Jianhua Ma, David Hunter, Changhai Ding, Zhaohua Zhu
Osteoarthritis (OA) is the commonest musculoskeletal disease worldwide, with an increasing prevalence due to aging. It causes joint pain and disability, decreased quality of life, and a huge burden...
-
Early Osteoarthritis Questionnaire (EOAQ): a tool to assess knee osteoarthritis at initial stage Thera. Adv. Musculoskelet. Dis. (IF 4.2) Pub Date : 2023-02-25 Alberto Migliore, Liudmila Alekseeva, Sachin R. Avasthi, Raveendhara R. Bannuru, Xavier Chevalier, Thierry Conrozier, Sergio Crimaldi, Gustavo C. de Campos, Demirhan Diracoglu, Gianfranco Gigliucci, Gabriel Herrero-Beaumont, Giovanni Iolascon, Ruxandra Ionescu, Jörg Jerosch, Jorge Lains, Emmanuel Maheu, Souz Makri, Natalia Martusevich, Marco Matucci-Cerinic, Karen Pavelka, Robert J. Petrella, Raghu
Background:Early stage of osteoarthritis (OA) is characterized by joint stiffness and pain as well as by subclinical structural changes that may affect cartilage, synovium, and bone. At the moment,...
-
Systemic lupus erythematosus is associated with increased risk of Parkinson’s disease Thera. Adv. Musculoskelet. Dis. (IF 4.2) Pub Date : 2023-02-13 In Young Kim, Yeonghee Eun, Jaejoon Lee, Kyungdo Han, Da Hye Kim, Ju-Hong Min, Hoon-Suk Cha, Eun-Mi Koh, Dong Wook Shin, Hyungjin Kim
Background:A small number of studies have suggested an association between systemic lupus erythematosus (SLE) and Parkinson’s disease (PD).Objectives:This study aimed to determine the risk of incid...
-
Nutritional and physical activity issues in frailty syndrome during the COVID-19 pandemic Thera. Adv. Musculoskelet. Dis. (IF 4.2) Pub Date : 2023-02-13 Maria Chiara Massari, Viviana Maria Bimonte, Lavinia Falcioni, Antimo Moretti, Carlo Baldari, Giovanni Iolascon, Silvia Migliaccio
‘Frailty’ has been described as ‘a state of increased vulnerability of the individual caused by an impairment of homeostasis as a result of endogenous or exogenous stress’. Frail individuals are de...
-
Prevalence and characteristics of giant cell arteritis in patients with newly diagnosed polymyalgia rheumatica – a prospective cohort study Thera. Adv. Musculoskelet. Dis. (IF 4.2) Pub Date : 2023-02-07 Lara C. Burg, Pantelis Karakostas, Charlotte Behning, Peter Brossart, Tanaz A. Kermani, Valentin S. Schäfer
Background:It is known that giant cell arteritis (GCA) and polymyalgia rheumatica (PMR) often occur together. So far, the prevalence of GCA in newly diagnosed PMR patients has not been evaluated in...
-
Association between baseline cardiovascular risk and incidence rates of major adverse cardiovascular events and malignancies in patients with psoriatic arthritis and psoriasis receiving tofacitinib Thera. Adv. Musculoskelet. Dis. (IF 4.2) Pub Date : 2023-02-07 Lars E. Kristensen, Bruce Strober, Denis Poddubnyy, Ying-Ying Leung, Hyejin Jo, Kenneth Kwok, Ivana Vranic, Dona L. Fleishaker, Lara Fallon, Arne Yndestad, Dafna D. Gladman
Background:Tofacitinib is a Janus kinase inhibitor for the treatment of psoriatic arthritis (PsA) and has been investigated for psoriasis (PsO).Objectives:This post hoc analysis examined baseline c...
-
A novel infrapatellar approach of ultrasound-guided intra-articular injection of the knee from both lateral and medial side: a case series Thera. Adv. Musculoskelet. Dis. (IF 4.2) Pub Date : 2023-01-31 King Hei Stanley Lam, Yung-Tsan Wu, Kenneth Dean Reeves, Admir Hadzic, Mario Fajardo Perez, Sau Nga Fu
Knee osteoarthritis (OA) is common. Ultrasound-guided intra-articular injection (UGIAI) using the superolateral approach is currently the gold standard for treating knee OA, but it is not 100% accu...
-
Cost-effectiveness of specialised manual therapy versus orthopaedic care for musculoskeletal disorders: long-term follow-up and health economic model Thera. Adv. Musculoskelet. Dis. (IF 4.2) Pub Date : 2023-01-31 Stina Lilje, Maurits van Tulder, Anders Wykman, Emmanuel Aboagye, Ulf Persson
Background:Physiotherapy is usually the first line of treatment for musculoskeletal disorders. If pain persists, an appointment with an orthopaedic surgeon is indicated, but many disorders for whic...
-
Fracture in clinical studies of tofacitinib in rheumatoid arthritis Thera. Adv. Musculoskelet. Dis. (IF 4.2) Pub Date : 2022-12-27 Karen E. Hansen, Mahta Mortezavi, Edward Nagy, Cunshan Wang, Carol A. Connell, Zaher Radi, Heather J. Litman, Giovanni Adami, Maurizio Rossini
Background:Preclinical data suggest that tofacitinib would protect bone health in patients with rheumatoid arthritis (RA).Objective:To assess fracture risk in tofacitinib RA clinical trials.Design:...
-
Latest advancements in imaging techniques in OA Thera. Adv. Musculoskelet. Dis. (IF 4.2) Pub Date : 2022-12-26 Daichi Hayashi, Frank W. Roemer, Thomas Link, Xiaojuan Li, Feliks Kogan, Neil A. Segal, Patrick Omoumi, Ali Guermazi
The osteoarthritis (OA) research community has been advocating a shift from radiography-based screening criteria and outcome measures in OA clinical trials to a magnetic resonance imaging (MRI)-bas...
-
The role of adipose-derived mesenchymal stem cells in knee osteoarthritis: a meta-analysis of randomized controlled trials Thera. Adv. Musculoskelet. Dis. (IF 4.2) Pub Date : 2022-12-26 Mohamad R. Issa, Ahmad S. Naja, Nour Z. Bouji, Bernard H. Sagherian
Background:Adipose-derived mesenchymal stem cells (ADMSCs) have recently been studied for the treatment of knee osteoarthritis. The goal is pain reduction and improvement of joint function leading ...
-
Hip replacement in femoral neck fractures: the role of cementation and its technical difficulties Thera. Adv. Musculoskelet. Dis. (IF 4.2) Pub Date : 2022-12-26 Elena Gasbarra, Eleonora Piccirilli, Chiara Greggi, Flavio Trapani, Riccardo Iundusi, Umberto Tarantino
Hip fractures in elderly patients are an arising problem due to aging of population and still represent a controversial challenge for orthopedic surgeon who should help achieve the best functional ...
-
Long-term efficacy and safety of neridronate treatment in patients with complex regional pain syndrome type 1: a pre-specified, open-label, extension study Thera. Adv. Musculoskelet. Dis. (IF 4.2) Pub Date : 2022-12-19 Massimo Varenna, Davide Gatti, Francesca Zucchi, Chiara Crotti, Vania Braga, Giovanni Iolascon, Bruno Frediani, Fabrizio Nannipieri, Maurizio Rossini
Background:No data on the permanent and curative effect of bisphosphonate treatment in patients with complex regional pain syndrome type-1 (CRPS-1) are currently available. The aim of this pre-spec...
-
Achievement of more stringent disease control is associated with reduced burden on workplace and household productivity: results from long-term certolizumab pegol treatment in patients with psoriatic arthritis Thera. Adv. Musculoskelet. Dis. (IF 4.2) Pub Date : 2022-12-13 William Tillett, Laura C. Coates, Sandeep Kiri, Vanessa Taieb, Damon Willems, Philip J. Mease
Background:Psoriatic arthritis (PsA) impacts the physical health and functional ability of patients, leading to reduced productivity. High unemployment rates and absence due to sickness have been r...
-
Pharmacokinetic boosting to enable a once-daily reduced dose of tofacitinib in patients with rheumatoid arthritis and psoriatic arthritis (the PRACTICAL study) Thera. Adv. Musculoskelet. Dis. (IF 4.2) Pub Date : 2022-12-12 Céleste J.T. van der Togt, Lise M. Verhoef, Bart J.F. van den Bemt, Nathan den Broeder, Rob ter Heine, Alfons A. den Broeder
Background:Tofacitinib is a Janus Kinase (JAK) inhibitor used for the treatment of rheumatoid arthritis (RA) and psoriatic arthritis (PsA), dosed as 5 mg twice daily (BID). It is primarily metaboli...
-
Neuro-PIMS-TS: a single case report and review of the literature Thera. Adv. Musculoskelet. Dis. (IF 4.2) Pub Date : 2022-12-12 Antonio Scarcella, Maria Vincenza Mastrolia, Edoardo Marrani, Ilaria Maccora, Ilaria Pagnini, Gabriele Simonini
Neurological manifestations related to SARS-CoV-2 infection in adults have been largely reported since the beginning of the pandemic. Subsequent large-scale studies involving children confirmed the...
-
The current state of the osteoarthritis drug development pipeline: a comprehensive narrative review of the present challenges and future opportunities Thera. Adv. Musculoskelet. Dis. (IF 4.2) Pub Date : 2022-12-07 Heungdeok Kim, Jinwon Seo, Yunsin Lee, Kiwon Park, Thomas A. Perry, Nigel K. Arden, Ali Mobasheri, Heonsik Choi
In this narrative review article, we critically assess the current state of the osteoarthritis (OA) drug development pipeline. We discuss the current state-of-the-art in relation to the development...
-
Sarcopenia and bone health: new acquisitions for a firm liaison Thera. Adv. Musculoskelet. Dis. (IF 4.2) Pub Date : 2022-11-28 Umberto Tarantino, Chiara Greggi, Virginia Veronica Visconti, Ida Cariati, Roberto Bonanni, Beatrice Gasperini, Italo Nardone, Elena Gasbarra, Riccardo Iundusi
Osteosarcopenia (OS) is a newly defined condition represented by the simultaneous presence of osteopenia/osteoporosis and sarcopenia, the main age-related diseases. The simultaneous coexistence of ...
-
Higher body mass index is associated with a lower iloprost infusion rate tolerance and higher iloprost-related adverse events in patients with systemic sclerosis Thera. Adv. Musculoskelet. Dis. (IF 4.2) Pub Date : 2022-11-22 Riccardo Bixio, Giovanni Adami, Eugenia Bertoldo, Alessandro Giollo, Andrea Morciano, Davide Bertelle, Giovanni Orsolini, Luca Idolazzi, Maurizio Rossini, Ombretta Viapiana
Background:Systemic sclerosis (SSc) is an autoimmune disease characterized by vasospasm and microvascular involvement. Iloprost (ILO), a prostaglandin analogous, is used for the treatment of SSc-re...
-
Health disparities in rheumatoid arthritis Thera. Adv. Musculoskelet. Dis. (IF 4.2) Pub Date : 2022-11-19 Elena I. Ciofoaia, Anjani Pillarisetty, Florina Constantinescu
Rheumatoid arthritis (RA) is an autoimmune disease characterized by joint inflammation that involves symmetric polyarthritis of small and large joints. Autoimmune rheumatic diseases represent a sig...